ES2229790T3 - Derivados de acido lipoico y su utilizacion para el tratamiento de enfermedades. - Google Patents

Derivados de acido lipoico y su utilizacion para el tratamiento de enfermedades.

Info

Publication number
ES2229790T3
ES2229790T3 ES99956698T ES99956698T ES2229790T3 ES 2229790 T3 ES2229790 T3 ES 2229790T3 ES 99956698 T ES99956698 T ES 99956698T ES 99956698 T ES99956698 T ES 99956698T ES 2229790 T3 ES2229790 T3 ES 2229790T3
Authority
ES
Spain
Prior art keywords
cells
acid
compound
lipoic acid
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99956698T
Other languages
English (en)
Spanish (es)
Inventor
Paul M. Bingham
Zuzana Zachar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Application granted granted Critical
Publication of ES2229790T3 publication Critical patent/ES2229790T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
ES99956698T 1998-10-26 1999-10-26 Derivados de acido lipoico y su utilizacion para el tratamiento de enfermedades. Expired - Lifetime ES2229790T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10562898P 1998-10-26 1998-10-26
US105628P 1998-10-26

Publications (1)

Publication Number Publication Date
ES2229790T3 true ES2229790T3 (es) 2005-04-16

Family

ID=22306916

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99956698T Expired - Lifetime ES2229790T3 (es) 1998-10-26 1999-10-26 Derivados de acido lipoico y su utilizacion para el tratamiento de enfermedades.
ES04077618T Expired - Lifetime ES2340488T3 (es) 1998-10-26 1999-10-26 Sales derivadas del acido lipoico y su utilizacion para el tratamiento de las enfermedades.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04077618T Expired - Lifetime ES2340488T3 (es) 1998-10-26 1999-10-26 Sales derivadas del acido lipoico y su utilizacion para el tratamiento de las enfermedades.

Country Status (12)

Country Link
US (2) US6331559B1 (cg-RX-API-DMAC10.html)
EP (3) EP2145883A1 (cg-RX-API-DMAC10.html)
JP (2) JP4728481B2 (cg-RX-API-DMAC10.html)
AT (2) ATE451362T1 (cg-RX-API-DMAC10.html)
AU (1) AU774362B2 (cg-RX-API-DMAC10.html)
BR (1) BR9914789A (cg-RX-API-DMAC10.html)
CA (1) CA2348998C (cg-RX-API-DMAC10.html)
DE (2) DE69941800D1 (cg-RX-API-DMAC10.html)
ES (2) ES2229790T3 (cg-RX-API-DMAC10.html)
IL (2) IL142824A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA01004152A (cg-RX-API-DMAC10.html)
WO (1) WO2000024734A1 (cg-RX-API-DMAC10.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
CA2352144A1 (en) * 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2162586B1 (es) * 1999-11-25 2002-07-01 Moraleda Manuel Gomez Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
IT1319196B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
ATE328877T1 (de) 2000-11-30 2006-06-15 Basf Ag Verfahren zur herstellung von liponsäure und dihydroliponsaüre
DE60234164D1 (de) * 2001-03-19 2009-12-10 Senju Pharma Co Neues a-liponsäurederivat und dessen verwendung
US6936641B2 (en) * 2002-06-25 2005-08-30 Johnson & Johnson Vision Care, Inc. Macromer forming catalysts
TWI272273B (en) * 2002-07-16 2007-02-01 Sonus Pharma Inc Platinum compounds
CN100367949C (zh) 2002-09-13 2008-02-13 有限会社绪方研究 黑色素消除制剂
AU2004212004B2 (en) 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US20040248982A1 (en) * 2003-06-09 2004-12-09 Dyer Gordon Wayne Use of compounds for the inhibition of proteins and UV protection
AU2004248187A1 (en) * 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
MY157827A (en) * 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
US7129368B2 (en) * 2004-03-15 2006-10-31 Sonus Pharmaceuticals, Inc. Platinum carboxylate anticancer compounds
US7582418B2 (en) * 2004-11-03 2009-09-01 Albion Laboratories, Inc. Antimicrobial chelates
EP1877060A2 (en) * 2005-04-28 2008-01-16 The Regents of the University of Colorado Therapeutic bifunctional compounds
WO2006118821A2 (en) * 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
US20070225354A1 (en) * 2006-03-21 2007-09-27 Eric Marchewitz Use of dihydrolipoamide for enhancing physical performance
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
ES2442901T3 (es) * 2007-04-18 2014-02-14 Cornerstone Pharmaceuticals, Inc. Derivados de ácido lipoico
MX2009011165A (es) * 2007-04-18 2009-12-09 Cornerstone Pharmaceuticals In Formulaciones farmaceuticas que contienen derivados del acido lipoico.
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
CN102089276A (zh) * 2008-03-04 2011-06-08 罗伯特·绍尔 酶结构、活性和/或表达水平的调节
AU2009251711B2 (en) 2008-04-01 2014-07-17 Antipodean Pharmaceuticals, Inc. Compositions and methods for skin care
KR20110025168A (ko) * 2008-04-04 2011-03-09 로버트 쇼어 약학적 조성물
US9073985B2 (en) 2008-07-14 2015-07-07 The Regents Of The University Of Colorado, A Body Corporate Methods and products for treating proliferative diseases
WO2010019225A1 (en) * 2008-08-15 2010-02-18 Robert Shorr Pharmaceutical composition
AU2009308152B2 (en) * 2008-10-21 2015-05-21 The General Hospital Corporation Cell transplantation
FR2937867B1 (fr) 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
WO2010062381A1 (en) * 2008-11-28 2010-06-03 Robert Shorr Organelle-specific drug delivery
BRPI0916476A2 (pt) * 2008-12-01 2016-02-16 Invasc Therapeutics Inc composição, método de tratamento para um distúrbio relacionado ao sistema renina-angiotensina-aldosterona, método para reduzir a resistência à insulina, método para tratar um distúrbio relacionado à síndrome metabólica
CN101787013B (zh) * 2009-01-22 2013-04-24 杭州民生药业有限公司 硫辛酰胺系列衍生物、制备方法及所述衍生物的制药用途
WO2010110887A1 (en) * 2009-03-24 2010-09-30 Robert Shorr Fatty acids
WO2010110771A2 (en) * 2009-03-25 2010-09-30 Frank Gibson Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
WO2011046583A1 (en) * 2009-09-11 2011-04-21 Robert Shorr Pharmaceutical exploitation of oxidative stress in transformed cells
WO2011138565A1 (fr) 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
FR2959668B1 (fr) * 2010-05-05 2012-07-13 Biorebus Association pharmaceutique contenant l'acide lipoique, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011146635A1 (en) * 2010-05-21 2011-11-24 North Texas Medical Associates Malignant neoplasm treatment protocol
JP6072684B2 (ja) 2010-08-06 2017-02-01 ザ ジェネラル ホスピタル コーポレーション ディー/ビー/エイ マサチューセッツ ジェネラル ホスピタル 細胞処置システムおよび細胞処置装置
BR112015014327A2 (pt) * 2012-12-19 2020-01-28 Cornerstone Pharmaceuticals Inc compostos farmacêuticos
US9605012B2 (en) 2013-01-17 2017-03-28 Garnett Mckeen Laboratory, Inc. Palladium-ruthenium-zinc-organo complexes and methods for their use in the treatment of inflammatory diseases
EP3189033B1 (en) 2014-06-19 2020-08-05 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
ES2747702T3 (es) 2014-06-19 2020-03-11 Rafael Pharmaceuticals Inc Compuestos farmacéuticos
US10052305B2 (en) 2015-10-07 2018-08-21 Buck Institute For Research On Aging Lipoic acid and derivatives thereof for the treatment of cystinuria
CN117263907B (zh) * 2023-09-23 2026-01-27 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用
CN117919421A (zh) * 2023-12-28 2024-04-26 石河子大学 转录因子klf7在制备抑制宫颈癌进展的药物中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362916C (de) 1921-08-13 1922-11-02 Eduard Duerr Abnehmbares Mikrometer fuer Schublehren
GB758897A (en) * 1953-10-19 1956-10-10 Merck & Co Inc Thio-substituted aliphatic carboxylic acids and their preparation
US2853497A (en) * 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2975198A (en) * 1954-07-08 1961-03-14 Research Corp Lipoic acid intermediates
US2872458A (en) * 1954-12-30 1959-02-03 Merck & Co Inc Addition product of a metal hydrocarbon mercaptide with an alpha-halogamma-butyrolactone
JPS57123107A (en) 1981-01-26 1982-07-31 Pola Chem Ind Inc Cosmetic
DE3512911A1 (de) * 1985-04-11 1986-10-16 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
DE3626116A1 (de) 1986-08-01 1988-02-11 Karl Thiel Thermostatische regeleinrichtung fuer heizungen bzw. heizaggregate
DE3629116A1 (de) * 1986-08-27 1988-03-10 Asta Pharma Ag Verfahren zur herstellung enantiomerenreiner r-(+)-(alpha)-liponsaeure und s-(-)-(alpha)-liponsaeure (thioctsaeure) sowie nonen- beziehungsweise mesylderivate als zwischenprodukte hierfuer
DE3900649A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
JPH03193758A (ja) * 1989-12-25 1991-08-23 Nisshin Oil Mills Ltd:The 新規γ―アミノ酪酸誘導体
ATE162715T1 (de) * 1991-07-05 1998-02-15 Asta Medica Ag Verwendung von schwefel enthaltenden carbonsäuren zur bekämpfung von pathophysiologisch bedingten erregungsstörungen
DE4137773A1 (de) * 1991-11-16 1993-05-19 Degussa Herstellung und verwendung von salzen der reinen enantiomere der (alpha)-liponsaeure
WO1994006794A1 (en) 1992-09-24 1994-03-31 National Institutes Of Health Aralkyl diazabicycloalkane derivatives for cns disorders
DE4310142A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Immunologisch aktive Konjugate und ein Verfahren zu ihrer Herstellung
US5463093A (en) 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE4439477C2 (de) * 1994-11-08 1999-10-21 Asta Medica Ag Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie
DE19601787C1 (de) * 1996-01-19 1997-07-24 Asta Medica Ag Herstellung und Verwendung von Salzen der 6,8-Bis(amidiniumthio)-octansäure
ATE310738T1 (de) * 1996-07-05 2005-12-15 Us Gov Health & Human Serv Gesättigte 1,2-dithiaheterocyclische verbindungen enthaltende antivirale pharmazeutische zubereitungen
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
WO1998043621A1 (en) * 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
JPH11124379A (ja) * 1997-10-17 1999-05-11 Ss Pharmaceut Co Ltd ジチオリリデンアセトアミド誘導体
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
ES2856125T3 (es) 2016-02-05 2021-09-27 Ea Pharma Co Ltd Derivado de sulfonamida y composición farmacéutica que contiene la misma

Also Published As

Publication number Publication date
EP1486495B1 (en) 2009-12-09
EP2145883A1 (en) 2010-01-20
JP2002528446A (ja) 2002-09-03
DE69941800D1 (de) 2010-01-21
CA2348998C (en) 2012-03-06
JP4728481B2 (ja) 2011-07-20
US6951887B2 (en) 2005-10-04
EP1124820A1 (en) 2001-08-22
MXPA01004152A (es) 2002-06-04
DE69920497T2 (de) 2006-02-09
IL142824A0 (en) 2002-03-10
AU774362B2 (en) 2004-06-24
EP1486495A1 (en) 2004-12-15
EP1124820B1 (en) 2004-09-22
WO2000024734A1 (en) 2000-05-04
AU1324600A (en) 2000-05-15
IL142824A (en) 2010-11-30
ATE277034T1 (de) 2004-10-15
CA2348998A1 (en) 2000-05-04
DE69920497D1 (de) 2004-10-28
US20020107234A1 (en) 2002-08-08
JP5727721B2 (ja) 2015-06-03
US6331559B1 (en) 2001-12-18
ES2340488T3 (es) 2010-06-04
BR9914789A (pt) 2001-10-02
ATE451362T1 (de) 2009-12-15
JP2010248203A (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
ES2340488T3 (es) Sales derivadas del acido lipoico y su utilizacion para el tratamiento de las enfermedades.
Lo et al. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer
ES2257821T3 (es) Derivados del acido cannabinol-11-oico utiles como agentes antiinflamatorios y analgesicos.
AU2010224866A1 (en) Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
ES2219607T3 (es) Nuevo agente inhibidor de la urocinasa.
AU2008298592A2 (en) Drug carriers
KR100861428B1 (ko) 암 치료용 지방산 유사체
ES2427088T3 (es) Estirilbencilsulfonas sustituidas para tratar trastornos proliferativos
JP6863742B2 (ja) 新規アントラニルアミドとその使用
CN101756957A (zh) 含有青蒿素及青蒿素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
JP2003511412A (ja) 正常細胞を化学療法剤の細胞毒性から保護するための方法
CN106176721A (zh) 有机硒化合物的癌症预防和治疗用途
ES2819175T3 (es) Compuestos farmacéuticos
CN106146372A (zh) 用于预防和治疗癌症的有机硒化合物
JP2004510761A (ja) 増殖性疾病を治療するための置換(e)−スチリルベンジルスルホン
CN102441167B (zh) 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
JP2009191041A (ja) ヒドロキシメチルケトン誘導体
CN103845325A (zh) 茶氨酸硝香酰胺在制备具有预防和治疗癌症等疾病的产品中的应用
EP1131082A2 (en) A method for treating tissue damaged from ischemia
EP1033130B1 (en) Inhibitor of urokinase production and of angiogenesis and its therapeutic use
AU687975B2 (en) Pharmaceutical compositions
CN106924235A (zh) 松萝酸在制备抗肿瘤药物增敏剂中的应用
CN111170980A (zh) 一种毛蕊异黄酮衍生物及其合成方法和应用
US9403791B1 (en) Coumarin derivatives for cancer therapy
CA2346053A1 (en) Angiogenesis inhibitor